STEP 5 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
September 2024 — Vol. 1, No. 9
Page 2 of 4 of this archive, newest first.
Also filed — page 2
the rolling newsroom, September 2024Independent analysis puts a Homopeptide orforglipron lot at 99.1%, against 98.4% on the certificate
The supplier confirmed the determination and supplied the method behind its own figure inside a week.
Inspectors cite Calder Vale Peptides of Skipton over sterility assurance
The observation that closes a facility is rarely the dramatic one.
The 9-day notice: how a compounding wind-down works in Singapore
The document is four pages. Three of them are about dates.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
The quiet end of the online reseller trading as Adamant Research Supply
A proper account of an operation that existed, and of what closing it cost.
A shortage listing ends. 18 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
STEP 8 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
From the floor in Suzhou: 8 posters, one theme
Reported from the sessions, and from the two hours afterwards.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
What a 32% rise in coupling-reagent prices does to a 2 mg vial
Follow the resin, not the catalogue.
SURMOUNT-1 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The 11-day notice: how a compounding wind-down works in the Netherlands
The document is four pages. Three of them are about dates.
The online reseller trading as Adamant Research Supply closes after 19 years
A proper account of an operation that existed, and of what closing it cost.
Australia health authority warns on falsified exenatide pens
Reported from the analysis, not from a warning notice.
Zhuhai export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
South Korea pharmacy body issues counselling standards for exenatide initiation
The evidence base is thin and the document says so, which is to its credit.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
Australia caps exenatide prescribing to 4 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
WXT names the synthesis and fill sites behind its catalogue
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Independent analysis puts a TFC mazdutide lot at 98.4%, against 95.9% on the certificate
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
Norway declines to reimburse semaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
What a 40% rise in coupling-reagent prices does to a 20 mg vial
Follow the resin, not the catalogue.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
The consolidator trading as Meridian Freight Partners closes after 6 years
A proper account of an operation that existed, and of what closing it cost.
HJ names the synthesis and fill sites behind its catalogue
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Nigeria health authority warns on falsified exenatide pens
Reported from the analysis, not from a warning notice.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
A shortage listing ends. 22 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.